Down-regulation of melanogenesis by phospholipase D2 through ubiquitin proteasome-mediated degradation of tyrosinase

J Biol Chem. 2004 Jun 25;279(26):27774-80. doi: 10.1074/jbc.M401786200. Epub 2004 Apr 5.

Abstract

The involvement of phospholipase D (PLD) in the regulation of melanogenesis was examined. Treatment of B16 mouse melanoma cells with 12-O-tetradecanoylphorbol-13-acetate (TPA) resulted in the activation of PLD and a decrease in melanin content. 1-Butanol, but not 2-butanol, completely blocked the TPA-induced inhibition of melanogenesis, suggesting the involvement of PLD in this event. Reverse transcription-PCR and immunoblot analyses revealed the existence of both PLD isozymes, PLD1 and PLD2, in B16 cells. When PLD1 or PLD2 was introduced into those cells by an adenoviral gene-transfer technique, both PLD1 and PLD2 were activated by TPA. When PLD1 and PLD2 were overexpressed, PLD2 potently caused a decrease in melanin content, whereas the effect of PLD1 expression on melanin content was minimal. Over-expression of PLD2 itself did not affect protein kinase C activity, as assessed by the intracellular distribution and levels of expression of each isoform expressed in B16 cells. The effects of TPA on the down-regulation of basal or alpha-melanocyte-stimulating hormone-enhanced melanogenesis were almost completely blocked by expressing a lipase activity-negative mutant, LN-PLD2, but not by LN-PLD1. Further, the PLD2-induced decrease in melanin content was accompanied by a decrease in the amount and activity of tyrosinase, a key enzyme in melanogenesis, whereas the mRNA level of tyrosinase was unchanged by the over-expression of PLD2. Moreover, treatment with proteasome inhibitors completely blocked the PLD2-induced down-regulation of melanogenesis. Taken together, the present results indicate that the TPA-induced down-regulation of melanogenesis is mediated by PLD2 but not by PLD1 through the ubiquitin proteasome-mediated degradation of tyrosinase. This suggests that PLD2 may play an important role in regulating pigmentation in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Butanol / pharmacology
  • Animals
  • Cysteine Endopeptidases / metabolism*
  • Cysteine Proteinase Inhibitors / pharmacology
  • Down-Regulation
  • Enzyme Activation / drug effects
  • Kidney / enzymology
  • Leupeptins / pharmacology
  • Lung / enzymology
  • Melanins / biosynthesis*
  • Melanoma, Experimental / metabolism
  • Mice
  • Monophenol Monooxygenase / antagonists & inhibitors*
  • Monophenol Monooxygenase / genetics
  • Monophenol Monooxygenase / metabolism
  • Multienzyme Complexes / antagonists & inhibitors
  • Multienzyme Complexes / metabolism*
  • Phospholipase D / antagonists & inhibitors
  • Phospholipase D / genetics
  • Phospholipase D / metabolism
  • Phospholipase D / physiology*
  • Proteasome Endopeptidase Complex
  • Protein Kinase C / genetics
  • Protein Kinase C / metabolism
  • Tetradecanoylphorbol Acetate / antagonists & inhibitors
  • Tetradecanoylphorbol Acetate / pharmacology
  • Ubiquitin / metabolism*
  • alpha-MSH / antagonists & inhibitors
  • alpha-MSH / pharmacology

Substances

  • Cysteine Proteinase Inhibitors
  • Leupeptins
  • Melanins
  • Multienzyme Complexes
  • Ubiquitin
  • alpha-MSH
  • 1-Butanol
  • Monophenol Monooxygenase
  • Protein Kinase C
  • phospholipase D2
  • Phospholipase D
  • phospholipase D1
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex
  • Tetradecanoylphorbol Acetate
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde